Washington, D.C. 20549







Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934




Date of Report (Date of earliest event reported): October 14, 2020



(Exact Name of Registrant as Specified in Charter)


Nevada   333- 191083   39-2080103

(State or other jurisdiction

of incorporation)

  (Commission File Number)   (IRS Employer Identification No.)


420 Lexington Avenue, Suite 2525, New York, NY

(Address of principal executive offices)   (Zip Code)


Registrant’s telephone number, including area code: 646-396-4087



(Former name or former address, if changed since last report)


Copies to:

Jeffrey Fessler, Esq.

Sheppard, Mullin, Richter & Hampton LLP

30 Rockefeller Plaza

New York, New York 10112

Telephone: (212) 653-8700

Facsimile: (212) 653-8701




Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).  Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o






Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;

Compensatory Arrangements of Certain Officers.


On October 15, 2020, the Board of Directors of Rasna Therapeutics, Inc. (the “Company”) appointed Willy Simon as Chairman of the Company. Mr. Simon replaces Alessandro Padova who resigned on October 14, 2020 for personal reasons. A press release announcing the appointment of Mr. Simon and the resignation of Mr. Padova is attached as Exhibit 99.1 hereto and incorporated herein by reference.


Item 9.01 Financial Statements and Exhibit.


(d) Exhibits.  
  99.1 Press Release, dated October 15, 2020.








Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


Date: October 15, 2020


  By:  /s/  Keeren Shah  
    Name:  Keeren Shah  
    Title:    Finance Director